Tag Archives: healthcare

Metro Pacific Hospitals Completes Investment by KKR

KKR

MANILA, Philippines–(BUSINESS WIRE)–Dec. 8, 2019– Metro Pacific Investments Corporation (“MPIC”) (PSE: MPI), global investment firm KKR, and GIC, Singapore’s sovereign wealth fund, today announced the completion of investments in Metro Pacific Hospital Holdings, Inc. (“Metro Pacific Hospitals” or the “Company”) by KKR and an affiliate of GIC (“GIC”). These were made through a series of transactions in common shares in Metro Pacific Hospitals and in mandatorily exchangeable bonds issued by MPIC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191208005083/en/

Proceeds from the sale of shares in the Company will be used to support Metro Pacific Hospitals’ potential investments in additional hospitals and new healthcare businesses. The capital will also be used to grow the Company’s existing subsidiaries, associates, and joint ventures.

Metro Pacific Hospitals is the operator of the largest private hospitals and healthcare network in the Philippines in terms of authorized bed capacity and revenues, with interests in 14 hospitals and approximately 3,200 beds across the country. The Company is focused on delivering high-quality healthcare solutions to patients at a time when more Filipinos are seeking premium medical services, driven by rising per capita incomes and rapid urbanization.

Manuel V. Pangilinan, Chairman of MPIC and Metro Pacific Hospitals, said, “We welcome KKR and GIC as investors who not only have established track records of helping healthcare companies to meet their growth ambitions, but also have full confidence in Metro Pacific Hospitals’ potential to provide even more critical healthcare services to patients across the Philippines. Today marks the start of a new and exciting chapter for Metro Pacific Hospitals.”

Augusto P. Palisoc Jr., President & CEO of Metro Pacific Hospitals, added, “The Philippine healthcare industry is poised for tremendous growth given the increasing demand for hospitals, clinics, and facilities that provide premium medical services. With this new investment, coupled with the expertise that KKR and GIC bring to Metro Pacific Hospitals, we will be in an even stronger position to meet patients’ needs and capture new opportunities through organic expansion, acquisitions and investments, and the adoption of new technologies.”

Jose Ma. K. Lim, President and CEO of MPIC, said, “The MPIC team is proud of Metro Pacific Hospitals and is pleased to have created and grown one of the largest and strongest hospital groups in the Philippines. We anticipate Metro Pacific Hospitals will continue to go from strength to strength alongside KKR and GIC, and we look forward to continuing our long-term partnership with the whole Metro Pacific team.”

Ashish Shastry, Co-Head of Asia Pacific Private Equity and Head of Southeast Asia at KKR, said, “Metro Pacific Hospitals is a world-class healthcare institution with a terrific team of doctors and medical practitioners who play a critical role in the lives of millions. We are excited to begin our work alongside this excellent team and look forward to supporting Metro Pacific Hospitals’ continued growth and development for healthcare providers and patients in the years to come.”

KKR made its investment from its flagship Asian Fund III.

About Metro Pacific Investments Corporation

Metro Pacific Investment Corporation is a publicly-listed, infrastructure investment firm in the Philippines, with holdings in Manila Electric Company, Global Business Power, Maynilad Water Services, Inc. and Metro Pacific Tollways Corporation. MPIC also holds investments in MPHHI, the Light Rail Manila Company and Metropac Movers Inc.

About Metro Pacific Hospital Holdings, Inc.

Metro Pacific Hospitals is the operator of the largest private hospitals and healthcare network in the Philippines in terms of authorized bed capacity and revenue, with interests in 14 hospitals nationwide, including eight hospitals in Metro Manila. The Company also has interests in an eight primary care clinics and eight cancer care centers, among other investments in allied healthcare services.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

About GIC

GIC is a leading global investment firm established in 1981 to manage Singapore’s foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate and infrastructure. In private equity, GIC invests through funds as well as directly in companies, partnering with its fund managers and management teams to help world class businesses achieve their objectives. GIC has investments in over 40 countries and has been investing in emerging markets for more than two decades. Headquartered in Singapore, GIC employs over 1,500 people across 10 offices in key financial cities worldwide.

For more information about GIC, please visit www.gic.com.sg or follow us on LinkedIn.

Source: KKR

Media:

For MPIC & Metro Pacific Hospitals:

David J. Nicol
EVP & Chief Financial Officer
Tel: +632 8888 0888

Augusto P. Palisoc, Jr.
CEO of MPHHI
Tel: +632 8888 0888

Melody M. Del Rosario
VP, PR & Corp. Comms.
Tel. +632 8888 0888

For KKR:

KKR Asia Pacific
Anita Davis
+852 3602 7335
anita.davis@kkr.com

KKR Americas

Kristi Huller & Cara Major
+1 212 750 8300
media@kkr.com

For GIC:

Mah Lay Choon
Senior Vice President
Corporate Affairs & Communications
+65 6889 6841
mahlaychoon@gic.com.sg

Wei Jun Ong
Associate
Corporate Affairs & Communications
+65 6889 8340
ongweijun@gic.com.sg

Categories: News

Tags:

EQT to sell Clinical Innovations

eqt

  • EQT Mid Market US and EQT Mid Market Asia III to sell Clinical Innovations, a leading global provider of medical devices for Labor & Delivery and Neonatal Intensive Care, to LABORIE for an Enterprise Value of USD 525m
  • During EQT’s ownership, Clinical Innovations has successfully transitioned from a distributor sales model to a direct sales force in select key markets, broadened its product portfolio in the Neonatal Intensive Care segment through product acquisitions and established a foothold in China

The EQT Mid Market US fund and the EQT Mid Market Asia III fund (jointly “EQT”) have entered into an agreement to sell Clinical Innovations (the “Company”) to LABORIE Medical Technologies (“LABORIE”) for an Enterprise Value of USD 525m. The EQT Mid Market US fund is the majority owner of Clinical Innovations.

Founded in 1993 and headquartered in Salt Lake City, Utah, Clinical Innovations is a leading global provider of medical devices for Labor & Delivery and Neonatal Intensive Care. The Company’s products, which include the Kiwi® Vacuum-Assisted Delivery System, Koala® Intrauterine Pressure Catheter and ebb® Complete Tamponade System, are used by clinicians in more than 90 countries to improve the lives of mothers and babies. Clinical Innovations also added SweetUms sucrose solution and the BoogieBaby oral and nasal suction device to its growing NICU product lineup earlier in December this year. Clinical Innovations operates a manufacturing facility in Utah and has approximately 250 employees around the world.

Together with the management team, EQT has supported Clinical Innovations in successfully transitioning from a distributor sales model to a direct sales force in select key markets, including parts of the United States, Western Europe and Australia. During EQT’s ownership, the Company has also successfully established a foothold in China and broadened its product portfolio within Neonatal Intensive Care.

“With the support of EQT, Clinical Innovations has significantly grown its global footprint and strengthened its product offering,” said Ken Reali, President and CEO of Clinical Innovations. “We look forward to continuing our growth journey with LABORIE and are confident that, together with our new partners, we will be well positioned to further positively impact mothers, babies and healthcare professionals on a large scale.”

“Clinical Innovations and the global network of clinicians who rely on its devices every day are crucial contributors to the health of mothers and babies,” said Brendan Scollans, Partner at EQT Partners and Investment Advisor to EQT Mid Market US. “We have been proud to support the development and growth of the company in partnership with the management team and look forward to following its continued success.”

“During EQT’s ownership, Clinical Innovations has strengthened its direct local presence in China, positioning the Company to capture future growth in one of the most promising markets,” said Jerry He, Partner at EQT Partners and Investment Advisor to EQT Mid Market Asia III. “LABORIE is a strong strategic fit for Clinical Innovations and we are confident that they will be an excellent partner for the Company.”

The transaction is subject to customary approvals and is expected to close in early 2020.

Moelis & Company LLC acted as financial advisor and Simpson Thacher & Bartlett LLP acted as legal advisor to EQT and Clinical Innovations.

Contact
US inquiries: Stephanie Greengarten, +1 646 687 6810, stephanie.greengarten@eqtpartners.com
International inquiries: EQT Press Office, +46 8 506 55 334, press@eqtpartners.com

About EQT
EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 41 billion in assets under management across 20 active funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 21 billion and approximately 127,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on Twitter and LinkedIn

About Clinical Innovations
Founded in 1993, Clinical Innovations is one of the largest medical device companies exclusively focused on labor and delivery and neonatal intensive care. The company is a market-leader in several categories with products such as the Kiwi® Vacuum-Assisted Delivery System, SweetUms sucrose solution, BoogieBaby oral and nasal suction device, Koala® Intrauterine Pressure Catheter, ROM Plus® Rupture of Membranes Test, traxi® Panniculus Retractor, ClearView® Uterine Manipulator, ebb® Complete Tamponade System and the babyLance™ Safety heel stick. Clinical Innovations is expanding its global presence while directly researching and developing state-of-the-art technologies and innovative medical devices that fulfill its mission of improving the lives of mothers and their babies throughout the world. For more information, visit clinicalinnovations.com.

Categories: News

Tags:

Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock

Abingworth

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 19, 2019– Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the pricing of the previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $2.75 per share. Exicure has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover overallotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 23, 2019 subject to customary closing conditions.

Exicure expects to receive gross proceeds of $27.5 million from the sale of common stock in the offering, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by it. Exicure intends to use the net proceeds from the offering to advance AST-008 through a Phase 1b/2 clinical trial; to initiate a second arm in its Phase 1b/2 clinical trial in cutaneous squamous cell carcinoma; to develop an SNA-based therapeutic candidate for the treatment of Friedreich’s ataxia, initiate IND-enabling studies and advance it into Phase 1 clinical trials; to develop a second SNA therapeutic candidate for a neurology condition and initiate IND-enabling studies; and for general corporate purposes.

Guggenheim Securities is acting as sole book-running manager for the offering. Chardan is acting as lead manager for the offering. H.C. Wainwright & Co. and Ladenburg Thalmann are acting as co-managers for the offering.

The securities described above are being offered by Exicure pursuant to a shelf registration statement on Form S-3 (No. 333-230175) that was declared effective by the Securities and Exchange Commission (SEC) on July 24, 2019. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website located at www.sec.gov. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained, when available, from: Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA.

Exicure Forward Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies, cash requirements and other matters as well as statements regarding the Company’s intention to conduct an offering and sale of securities, the size of the offering, the completion of the offering and the expected use of proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement (including without limitation its cash runway guidance) or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Exicure, Inc.

MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com

 

 

Categories: News

Tags:

Median Technologies announces the signing of a € 35 million finance contract with the European Investment Bank (EIB)

Abingworth

18 December 2019, Sophia Antipolis, France – Brussels, Belgium

Press release – For immediate release – 05:45pm CET

 Median Technologies announces the signing of a € 35 million finance contract with the European Investment Bank (EIB)

  • This finance contract will enable Median Technologies to accelerate its investment program for the iBiopsy® imaging phenomics platform
  • Median expects the disbursement of the first tranche of € 15 million during the first semester of 2020

Median Technologies, The Imaging Phenomics Company (Euronext Growth – ALMDT) and the European Investment Bank (EIB) announced today the signing of a € 35 million finance contract, supported by the European Strategic Investment Fund (EFSI) or “Juncker Plan”. News about ongoing negotiations for this loan was previously released on May 15, 2019.

This financing, divided into three (3) tranches, will enable Median Technologies to enhance and accelerate its iBiopsy® imaging platform investment program for the coming years. Median is a cutting-edge AI and data sciences technology provider for precision medicine. Through its proprietary iBiopsy® platform, Median is developing non-invasive imaging biomarkers to enable the identification of certain chronic disease – including cancer- signatures, to dramatically enhance early detection, severity quantification and monitoring of diseases. The objective is on one hand to guide clinicians in their therapeutic decisions in the context of precision and predictive medicine and, on the other hand, to provide disruptive decision tools to foster medical innovations and new therapy development.

Median will request the disbursement of the first tranche of € 15 million during the first semester of 2020. The contract then provides for the disbursement of the second and third tranches (of € 10 million each) in the coming years, at Median Technologies’ discretion, subject to the completion of certain conditions precedents specified in the finance contract. The repayment of this financing will occur, in a single installment, at the end of a five -year period after the disbursement date. The finance contract is supplemented by the payment of various interests and fees and by a guarantee granted by Median Technologies, Inc. (Median Technologies’ US subsidiary).

Pursuant to the warrants issuance agreement, Median Technologies will issue 800,000 warrants for the benefit of the EIB on the date of disbursement of the first tranche and, where appropriate, 300,000 additional warrants on the date of disbursement of the second tranche, at a subscription price of € 0.01. The exercise price of these warrants  will be determined based on the price of one or more fundraising(s) of at least € 15 million carried out within 15 months after the subscription date to which an increasing discount will apply based on time, with a minimum of € 2 from the 16th month. The lifespan of these warrants is 15 years.

The warrants issuance agreement includes an exercise parity adjustment clause which could apply, under certain conditions,in case of capital increase. The EIB will be granted with the possibility, under certain conditions, to request Median Technologies to buy back its warrants for a maximum amount of € 50 million and, beyond that amount, to find a buyer and pay interests on the price of the remaining warrants. The total amount of warrants (for the two tranches) would represent up to 7.44 % of the share capital fully diluted.

The objective of this financing, granted by the EIB together with the European guarantee within the framework of the Juncker plan, is to support research and innovation projects developed by companies with substantial growth potential. Median Technologies meets these criteria as its technologies have the potential to impact the lives of hundreds of thousands of patients worldwide.

The agreement was signed by the European Investment Bank and Fredrik Brag, CEO and co-founder of Median Technologies on December 18, 2019.

“Through the Juncker Plan impulse, EIB has become a key player in financing innovative companies, in particular companies involved in the domains of Health and Artificial intelligence, which are the core activities developed by Median Technologies “, said EIB Vice-President, Mr. Ambroise Fayolle

Fredrik Brag, CEO and co-founder of Median Technologies added: “We are very pleased to announce the signing of the finance agreement with the European Investment Bank. The EIB financing will allow us to accelerate our investment in the development of our iBiopsy® platform with a strong focus in oncology and liver disease. We are the next generation precision medicine company focused on helping conquer cancer and other diseases through our proprietary routine imaging tests.  These novel non-invasive imaging tests could dramatically impact early detection, diagnosis and monitoring of diseases.  We leverage our capabilities in technology, artificial intelligence, clinical development, regulatory and reimbursement to drive the development and commercial adoption of our future iBiopsy® product line, improve patient clinical outcome and lower healthcare costs.”     

Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Median’s management believes that the expectations reflected in such forward looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Median, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities such as the absence of guarantee that the service if approved will be commercially successful, the future approval, Median’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares  outstanding as well as those discussed or identified in the public filings with the AMF made by Median, other than as required by applicable law, Median does not undertake any obligation to update or revise any forward-looking information or statements.

Previous

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT).

Contacts

Median Technologies

Emmanuelle Leygues
Head of Corporate Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Actifin  (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP  (Press)

Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com

About the European Investment Bank (EIB) and the Juncker Plan

Created by the Treaty of Rome in 1958, the EIB is the EU bank, which, together with its dedicated SME support subsidiary the European Investment Fund (EIF), forms the EIB Group. The EIB Group provides its financing and know-how for sound and sustainable investment projects meeting EU objectives.

Supported by its expertise and the financial attractiveness lent by its AAA rating, the EIB Group is a key player in getting investment back on track in Europe. It supports the real economy while also attracting other investors by financing concrete projects with an impact on people’s lives. EUR 8.6bn of new financing was allocated to support high quality growth and job driving projects in France in 2017.

Website: www.eib.org/press

The Investment Plan for Europe:  the so-called Juncker Plan, is one of Jean-Claude Juncker’s top priorities. It focuses on boosting investments in Europe to create jobs and growth by making smarter use of new and existing financial resources, removing obstacles to investment and providing greater visibility and technical assistance to investment projects. The European Fund for Strategic Investments (EFSI), which is the central pillar of the Investment Plan for Europe, enables the EIB Group to invest in more, often riskier, projects with high added value. EFSI is already showing concrete results. The projects and agreements approved for financing under EFSI so far have mobilised EUR 408.4bn in investments, of which EUR 69bn is in France. The plan is supporting around 952 000 SMEs across all 28 Member States.

Contacts

Cyrille Lachèvre
+ 33 (0)6 20 42 12 08
c.lachevre@ext.eib.org

Previous

Categories: News

Tags:

paraDIGMA Group and BlijWerkt Announce Collaboration with Support from Mentha Capital

Mentha Capital

paraDIGMA Group and BlijWerkt are to enter into collaboration and will form a new group. Investor Mentha Capital will take a majority stake in the combination of the two service providers which operate in the field of sustainable employability and provide employment to over 400 employees. The transaction is subject to the approval of the Dutch Healthcare Authority (NZa).

The collaboration creates a strong and fast-growing combination which challenges the established order with its innovative methods. The combination offers a wide range of services where an integral approach and personal approach are central. The two companies already have 500,000 affiliated employees throughout the country. Customers will benefit from the complementary service package of both companies and the focus on sharing knowledge and capacity.

paraDIGMA Group is a fast-growing group of companies operating in the field of sustainable employability. Its occupational health and safety services provider Argo Advies takes a unique approach to absenteeism, leading to progressive and highly effective absenteeism and health policies within organizations. The group also offers psychological interventions, outplacement and reintegration, labour research and advice, and business training. The paraDIGMA Group was founded in 2000 by Rudo Vissers. Mr Vissers will stay on as director and remain a shareholder in the combination.

BlijWerkt is an occupational health and safety service currently under the control of investment company Gilde Healthcare. It has become a successful, leading and nationally operating player where personal attention to its clients is central.

Mentha Capital will take over the shares in both companies from the current shareholders. Mentha invests in established, profitable companies which demonstrate clear potential for further expansion through organic growth, expansion into new markets and/or acquisitions. Mentha has 15 participations, active in various end-markets.

Rudo Vissers of paraDIGMA Group: “We are very pleased to have taken this step. The result is a unique and very solid company with a strong position in the market and major social significance. We continue to look at sustainable employability from the perspective of leadership and culture in organizations, reinforced by a high-quality medical base.”

Ruud Pels, BlijWerkt: “I am grateful to Gilde for having supported the development of our company. I look forward to working with Mentha and the paraDIGMA Group. Utilizing the expertise of the paraDIGMA Group in areas in which we at BlijWerkt are less active, enables us to serve our customers even better in the future.”

Barend Rutten, Mentha Capital: “Sustainable employability is an increasingly important theme for companies and society where the demand for effective and innovative service is increasing. By joining forces, paraDIGMA and BlijWerkt can further improve the quality and service they provide to customers and lay a solid foundation for further growth.

Gilde Healthcare reflects with satisfaction on its involvement with BlijWerkt: “as a sector specialist with an active growth strategy we have been able to add a lot of value to our investment in BlijWerkt,” commented Hugo de Bruin, partner at Gilde Healthcare, “we are convinced BlijWerkt will continue its succesful strategy together with paraDIGMA Group in the years to come.”

Categories: News

Tags:

Bassem Saleh appointed new CEO of TFS

Ratos

Bassem Saleh has been appointed new CEO of TFS. Bassem is Chief Medical Officer at TFS and Executive Vice President of Clinical Development Services, the largest Business Area at TFS. He will assume his role as CEO today, 17 December. János Filakovský is stepping down from his position as CEO and leaving the company.

Bassem Saleh has solid executive leadership skills and long industry experience from both CROs (Contract Research Organisations) and Biopharma including Premiere Research, ICON, PRAHS and Chugai (Roche group). Most recently Bassem has been heading up TFS largest Business Area Clinical Development Services (CDS) with strong results and is an appreciated leader in the company. Bassem is a medical doctor specialized in Pharmaceutical Medicine and Oncology.

“Bassem has impressed the board of TFS with the results he has delivered in the business. He is an appreciated leader at TFS and with his background from the industry we believe he is an ideal person to further develop TFS as CEO. We thank János for his contributions to TFS,” says Jonas Wiström, CEO of Ratos and Business Area President Industry.

Ratos became an owner of TFS in 2015. On behalf of its customers, the company conduct clinical trials in more than 40 countries worldwide and works with a broad international customer base of leading research companies. Revenues for the rolling 12 months at 30 September 2019 amounted to 86.0 MEUR and EBITA was 1.8 MEUR.

 

For further information, please contact:
Jonas Wiström, President and CEO, Ratos, +46 8 700 17 00
Per Magnusson, Chairman TFS and Director Operations, Ratos, +46 70 676 64 26
Helene Gustafsson, Head of IR and Press, Ratos, +46 70 868 40 50

Categories: News

Tags:

Ampersand Capital Partners Acquires Peptides International And Merges Company With New England Peptide

WELLESLEY, Mass., GARDNER, Mass. and LOUISVILLE, Ky., Dec. 16, 2019 /PRNewswire/ — Ampersand Capital Partners announced today that it has completed the acquisition of Peptides International and merged it with existing portfolio company New England Peptide. This merger brings together two leading providers of peptide synthesis services as well as a broad catalog of unique peptide products to assist in drug discovery and diagnostic product development endeavors around the world.

Based in Louisville and founded in 1983, Peptides International is a global leader in catalog and custom peptide production, providing high-quality synthesis services to an extensive range of pharmaceutical, biotech, and other life science customers. Peptides International is specialized in addressing the most complex peptide projects and offers customers full chemical optimization and scale-up services.

“New England Peptide is excited to announce that in our 20th year as a custom peptide synthesis company, we have merged with Peptides International,” said Sam Massoni, CEO of New England Peptide. “This transaction adds meaningful scale, capabilities, customer relationships, and a similarly strong market reputation to what we have built at New England Peptide.”

Jackie Spatola, current CEO of Peptides International added: “Ampersand Capital’s acquisition of PI enables high-quality custom peptide market development, which fortifies our 35-year-old company’s world leader strategy and position. We look forward to offering even better services to our worldwide customer base through working with New England Peptide.”

José de Chastonay, Chairman of the Board added: “Whereas New England Peptide has a leading position in manufacturing thousands of small-scale peptides and antibody related services, Peptides International is best known for making larger-scale quantities of high-quality custom peptides and for maintaining a unique catalog of off-the-shelf products. The combination of the two companies creates a comprehensive, “one-stop-shop” for non-GMP peptides.”

“Ampersand’s goal with our original investment in New England Peptide earlier this year was to build a world-class leader in peptide synthesis services, and this transaction furthers that goal,” stated Eric Lev, Partner at Ampersand. “Ampersand looks forward to working with the management team in the next phase of organic and inorganic growth as the company strives to provide industry-leading peptide solutions to the biotechnology, pharmaceutical, and academic markets.”

About New England Peptide

Established in 1998, New England Peptide designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations worldwide. Headquartered in Gardner, MA, the company specializes in custom peptide synthesis, polyclonal antibody production, stable-labeled bioanalytical peptide standards, and catalog peptide products. New England Peptide operates in a 25,000 square foot facility with significant laboratory space to service all customer and regulatory requirements. Additional information about New England Peptide is available at www.newenglandpeptide.com.

About Peptides International

Peptides International, headquartered in Louisville, Kentucky, specializes in manufacturing and distributing high purity, biologically active peptides, enzyme substrates and inhibitors, innovative polymers and related products, and custom peptide synthesis services to life sciences and research institutions throughout the world. Founded in 1983, the company operates out of a 12,000 square foot facility certified to ISO 9001:2015. Additional information about Peptides International is available at www.pepnet.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand is available at ampersandcapital.com.

Related Links
http://ampersandcapital.com

Categories: News

Tags:

Partners Group to acquire EyeCare Partners, a leading US medical vision services provider

Partners Group

Partners Group, the global private markets investment manager, has agreed to make a significant equity investment on behalf of its clients in EyeCare Partners LLC (“ECP” or “the Company”), the largest vertically integrated medical vision services provider in the US. Partners Group will become the majority shareholder, while ECP’s management team and physician partners will continue to maintain a substantial equity stake. The transaction is expected to close in the first quarter of 2020.

Founded in 2015 and headquartered in St. Louis, Missouri, ECP has an extensive network of full-scope medical optometry and ophthalmology practices, with over 450 locations across 13 states throughout the US. The Company employs over 500 optometrists and 85 ophthalmologists who, together with over 4,400 clinic staff, offer patients end-to-end services covering medical optometry, ophthalmology and sub-specialties, and vision correction products. ECP’s model provides an integrated network of services that cover the entire lifecycle of a patient’s eye care needs, which results in increased patient and physician satisfaction and retention.

Following the investment, Partners Group will work closely with ECP’s management team, led by Chief Executive Officer Kelly McCrann, on strategic initiatives to support ongoing organic and acquisitive growth. Key areas of focus for these initiatives will include the following: increasing the recruitment of high-quality ophthalmologists and optometrists; optimizing the network model; expanding and maximizing ambulatory surgical center utilization; enhancing administrative processes and operating efficiencies; investing in clinical technologies that enhance patient care; and pursuing select M&A partnership opportunities that provide world-class medical vision care and patient experience.

Kelly McCrann expresses the following: “Partners Group has excellent operational support capabilities and an extremely successful track record of working with high-growth companies to build critical mass in the highly fragmented US healthcare sector. We are thrilled to have found a long-term partner that shares our patient- and physician-centric outlook. We are very excited to work with Partners Group to both strengthen ECP’s offering and expand our presence throughout the US.”

Todd Miller, Managing Director, Co-Head Private Equity Directs Americas, Partners Group, states: “As the largest medically focused and integrated eye care services provider in the US, ECP is a market outperformer with strong momentum in a growing industry. We are excited to bring our operational experience with multi-site healthcare operations into partnership with ECP’s talented management team and physician partners, who share Partners Group’s focus on ensuring patient care remains at the forefront of operational decisions. We look forward to working together with Kelly and the entire team to enhance patient care, expand geographically, and build local density, among other things.”

Remy Hauser, Managing Director, Head of Healthcare Industry Value Creation, Partners Group, adds: “Our Thematic Sourcing efforts over the past 24 months identified the medical vision segment as a highly attractive sub-sector within the healthcare sector, ripe for organic growth, expansion, and consolidation. ECP’s vertically integrated model, offering the full spectrum of medical eye health solutions and one network for scheduling, billing and coordination, provides a competitive advantage as it creates a better experience, improved medical outcomes, and retention for patients, physicians and medical providers.”

Kirkland & Ellis LLP represented Partners Group in the transaction.

Categories: News

Tags:

Observe Medical ASA listed on Oslo Axess

Reiten

Observe Medical ASA was listed on Oslo Axess the 4th of November 2019. The company is a spin-off from Navamedic and contains their Medtech division. Observe medical has developed the first digital urine meter for use in intensive care units that can transfer data wireless to the patient data management system, called Sippi®. Sippi® is now undergoing the final tests and is ready for commercialization.

Observe Medical will have its headquarter in Oslo, Norway and their operational business in Stockholm and Gothenburg, Sweden. The current focus is within urology where its products contribute to increased patient safety and a more efficient care system.

Sippi® BLE 2.0 is the first digital urine meter for use in intensive care units that can transfer data wireless to the patient data management system. Sippi® also comprises the unique technology Sippcoat®, which prevents bacterial migration in closed collection systems. Sippi® is CE marked according to the new Medical Device Directive and is currently being launched at selected hospitals in the Nordics and Germany.

Categories: News

Tags:

Laborie, a subsidiary within Patricia Industries, acquires global leader in childbirth and neonatal medical products for USD 525m

Investor

As announced yesterday, Laborie has entered an agreement to acquire Clinical Innovations, a leading provider of single-use, clinician-preferred products for hospital labor & delivery and neonatal intensive care unit departments. Key products include the Kiwi Complete Vacuum Delivery System, which is used in complicated childbirth procedures and the Koala Intrauterine Pressure Catheter, which monitors the strength of contractions during childbirth.

In 2019, Clinical Innovations’ revenues are expected to amount to approximately USD 70m. The company has a track record of high organic growth, as well as strong profitability and cash conversion.

The total consideration amounts to USD 525m on a debt-free basis, which will be funded mainly by equity from Patricia Industries.

“Within Patricia Industries we have built a number of great platform companies with leading market positions in attractive niches. To profitably grow these companies is a key priority. The acquisition of Clinical Innovations is a highly attractive addition to Laborie’s existing operations”, comments Investor CEO Johan Forssell.

“Laborie has a market-leading product portfolio in urology and gastroenterology and multiple opportunities to accelerate growth in new and existing markets globally. Contributing additional capital to Laborie to acquire a high quality business with a similarly strong position in market segments benefitting from multiple long-term growth drivers, is an attractive investment proposition”, comments Noah Walley, Co-Head Patricia Industries.

The acquisition is subject to approval by relevant competition authorities and is expected to be completed during the first quarter, 2020.
About LABORIE Medical Technologies
LABORIE is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used in gastrointestinal procedures and for the diagnosis and treatment of pelvic health in the Urology, Gynecology, and Colorectal fields. Laborie is a portfolio company of Patricia Industries.

About Patricia Industries
Patricia Industries, a part of Investor AB, makes control investments in leading companies with strong market positions, brands and corporate cultures within industries positioned for secular growth. Our ambition is to be the sole owner of our companies, together with strong management teams and boards. We invest with an indefinite holding period, and focus on building durable value and capturing organic and non-organic growth opportunities.

Downloads

Company information

Contact information

Categories: News

Tags: